Treatment comprises topical application to the eye of 5- 1-hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl salicylamide (Ia) of the formula (I) or its salt. Normally the cpd. which lowers intraocular pressure is used in a concn. of 0.1-5 wt. % in a topical opthalmic carrie. The disclosure also refers to the use of cpds. of formula (II) and salts, where X is -CH2)2-, -CH2- or -OCH2- and Y is phenyl or o- or p-methoxyphenyl, in the foregoing treatment.
展开▼
